Abstract
Background: The role of p53 and p21 as prognostic factors and response-parameters for adjuvant therapy in colorectal carcinomas are still under controversial debate. We aimed to evaluate the importance of both genes in a prospectively documented patient cohort. Patients and methods: Collection of follow-up data of 125 patients with sporadic colorectal carcinoma (stage UICC II/III), who underwent curative resection between 1995 and 2001. The median follow-up time was 51,8 ± 2,5 months. We investigated the protein expression of p53 and p21 in tumour tissues by immunohistochemistry. The probability of overall survival as a function of time was determined by the Kaplan-Meier method. Differences in survival curves were compared by the log rank test. Results: Patients had a 5-year overall survival rate of 64 % and a progression-free survival rate of 62 %. We observed an expression of p53 in 63 % and of p21 in 26 % of the carcinomas. In univariate survival analysis, p53 expression was associated with a significant better overall survival (p = 0,048). Negative p21 expression was significantly related to a better progression-free (82,4 ± 4,8 months; p = 0,02) and overall survival (83,9 ± 4,5 months; p = 0,005). In a subgroup analysis, we found a significant survival advantage for patients with p21-negative/p53-positive carcinomas. The progression-free survival was 86,5 ± 5,9 months (p = 0,007) and the overall survival 94,5 ± 5,0 months (p < 0,0001) as compared to other subgroups p21−/p53−, p21+/p53+, p21+/p53−. Adjuvant therapy revealed a benefit in overall survival in patients with p21-negative carcinomas as compared to patients without therapy (90,7 ± 4,7 vs. 58,3 ± 6,1 months, p = 0,017). Patients with p21-negative/p53-positive carcinomas had a favourable overall survival after adjuvant therapy (99,4 ± 4,8 vs. 66,9 ± 6,8 months, p = 0,012). Conclusion: The cell cycle regulator p21 has prognostic impact on patient survival as well as effects on adjuvant therapy. Moreover, the combination of p21−/p53+ expression in colorectal carcinomas might be particularly important.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Bhonde MR, Hanski ML, Notter M, Gillissen BF, Daniel PT, Zeitz M, Hanski C (2006) Equivalent effect of DNA damageinduced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene 25: 165–175
Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dorken B, Daniel PT (2003) Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21: 3391–3401
Schwandner O, Bruch HP, Broll R (2002) p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance? Int J Colorectal Dis 17: 11–19
Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L (2003) PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 100: 1931–1936
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this paper
Cite this paper
Lipka, S., Noske, A., Müller, K., Buhr, H.J., Kruschewski, M. (2008). Prognostische Relevanz von p21, p53 und deren Bedeutung als Response-Parameter für die adjuvante Therapie des kolorektalen Karzinoms. In: Arbogast, R., Schackert, H.K., Bauer, H. (eds) Chirurgisches Forum 2008. Deutsche Gesellschaft für Chirurgie, vol 37. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78833-1_42
Download citation
DOI: https://doi.org/10.1007/978-3-540-78833-1_42
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-78821-8
Online ISBN: 978-3-540-78833-1
eBook Packages: Medicine (German Language)